Stephen Neil Petty Valenzuela, Sinead E Miller, Charleson S. Bell, T. Giorgio
Bacteremia and related syndromes such as sepsis and septic shock are becoming an increasing health concern due in large part to the rise of antibiotic resistance and unmet challenges for rapid diagnosis. Extracorporeal bacterial separation methods are currently under development to identify pathogens and reduce bacterial load. Previous studies have generated models to understand the progression of bacteremia. Here, a physiologically-based pharmacokinetic model was integrated with a physically-based magnetic separation model to inform the design of a micromagnetic separation device. This modeling demonstrates that smallfootprint microfluidic devices are not efficient enough for bacteremia treatment in large living systems and further research into high-throughput extracorporeal blood-cleansing devices is required.
{"title":"Optimization of Micromagnetic Separation for Bacteremia Treatment","authors":"Stephen Neil Petty Valenzuela, Sinead E Miller, Charleson S. Bell, T. Giorgio","doi":"10.11159/ijtan.2017.004","DOIUrl":"https://doi.org/10.11159/ijtan.2017.004","url":null,"abstract":"Bacteremia and related syndromes such as sepsis and septic shock are becoming an increasing health concern due in large part to the rise of antibiotic resistance and unmet challenges for rapid diagnosis. Extracorporeal bacterial separation methods are currently under development to identify pathogens and reduce bacterial load. Previous studies have generated models to understand the progression of bacteremia. Here, a physiologically-based pharmacokinetic model was integrated with a physically-based magnetic separation model to inform the design of a micromagnetic separation device. This modeling demonstrates that smallfootprint microfluidic devices are not efficient enough for bacteremia treatment in large living systems and further research into high-throughput extracorporeal blood-cleansing devices is required.","PeriodicalId":31009,"journal":{"name":"RAN","volume":"5 1","pages":"27-35"},"PeriodicalIF":0.0,"publicationDate":"2017-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85193918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Juan Mejía-Trejo, Zaira Yunuen Garcia-Carvaja, Gilberto Israel González-Ordaz
{"title":"Management Innovation in Nanotechnology Sector: The First Insights in México","authors":"Juan Mejía-Trejo, Zaira Yunuen Garcia-Carvaja, Gilberto Israel González-Ordaz","doi":"10.11159/ICNNFC17.115","DOIUrl":"https://doi.org/10.11159/ICNNFC17.115","url":null,"abstract":"","PeriodicalId":31009,"journal":{"name":"RAN","volume":"44 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79938134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Karumbaiah N. Chappanda, S. Ilyas, S. Kazmi, J. Holguin, P. Costa, M. Younis
K. N. Chappanda, S. Ilyas, S. N. R. Kazmi, J. Holguin, P. M. F. J. Costa and M. I. Younis Nano/Micro Mechanics and Motion Laboratory Laboratory for Carbon Nanostructures Physical Science and Engineering Division, King Abdullah University of Science and Technology Thuwal, 23955-6900, Kingdom of Saudi Arabia jorge.holguinlerma@kaust.edu.sa; pedro.dacosta@kaust.edu.sa; karumbaiah.nanaiah@kaust.edu.sa saad.ilyas@kaust.edu.sa; syed.kazmi@kaust.edu.sa; mohammad.younis@kaust.edu.sa
K. N. Chappanda, S. Ilyas, S. N. R. Kazmi, J. Holguin, P. M. F. J. Costa和M. I. Younis纳米/微力学与运动实验室碳纳米结构物理科学与工程系实验室，沙特阿拉伯王国图沃尔，23955-6900 jorge.holguinlerma@kaust.edu.sa;pedro.dacosta@kaust.edu.sa;karumbaiah.nanaiah@kaust.edu.sa saad.ilyas@kaust.edu.sa;syed.kazmi@kaust.edu.sa;mohammad.younis@kaust.edu.sa
{"title":"A Reprogrammable Universal Logic Gate Based on a Nano Cantilever Resonator","authors":"Karumbaiah N. Chappanda, S. Ilyas, S. Kazmi, J. Holguin, P. Costa, M. Younis","doi":"10.11159/icnnfc17.101","DOIUrl":"https://doi.org/10.11159/icnnfc17.101","url":null,"abstract":"K. N. Chappanda, S. Ilyas, S. N. R. Kazmi, J. Holguin, P. M. F. J. Costa and M. I. Younis Nano/Micro Mechanics and Motion Laboratory Laboratory for Carbon Nanostructures Physical Science and Engineering Division, King Abdullah University of Science and Technology Thuwal, 23955-6900, Kingdom of Saudi Arabia jorge.holguinlerma@kaust.edu.sa; pedro.dacosta@kaust.edu.sa; karumbaiah.nanaiah@kaust.edu.sa saad.ilyas@kaust.edu.sa; syed.kazmi@kaust.edu.sa; mohammad.younis@kaust.edu.sa","PeriodicalId":31009,"journal":{"name":"RAN","volume":"313 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77245528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sara S. Nogueira, J. Moreno, H. Haas, K. Reuter, Stephanie Erbar, Peter Languth
Extended Abstract Messenger RNA (mRNA)-based nanomedicines constitute a new class of pharmaceutical products, with a variety of potential applications, ranging from tumour immunotherapy to protein substitution. For patient administration, mRNA can be formulated in different types of nanoparticle vehicles, in order to protect the mRNA from degradation and facilitate uptake resulting in expression at the target site. BioNTech has brought the first intravenously injectable mRNA nanoparticle product for cancer immunotherapy into clinical trials, which consist of a lipoplex formulation obtainable from cationic liposomes [1, 2]. Lipid nanoparticles (LNPs) are another type of delivery vehicle and have been successfully used in the past, for example, to deliver siRNA to the liver [3]. Recently, LNPs have been also been used as carriers for mRNA, for induction potent CD8 T cell immune response [4], showing that LNPs can be versatile delivery systems for RNA in diverse therapeutic settings. Typically, LNPs are comprised of an ionizable lipid, one or several helper lipids and a polyethylene glycol (PEG). The ionizable lipid, which is positively charged at low pH and neutral at high pH, is selected to allow high RNA encapsulation and efficacy and to facilitate endosomal escape. The activity of the mRNA LNP formulations strongly depends on the type of ionisable lipid, on the lipid composition, the lipid to RNA ratio, and several other molecular and structural parameters. Furthermore, the activity may vary also for different application routes (e.g., intravenous, intramuscular, subcutaneous), or if therapeutic approaches are intended. So far, there is no clear common understanding on the correlation between the molecular parameters of the LNPs and the biological activity. Therefore, in our study we have systematically studied certain molecular and formulation parameters of mRNA loaded LNPs, in order to correlate them with the biological function. In particular we have thoroughly investigated physicochemical characteristics (internal organization, fluidity, size) and the structure of the LNPs (in particular by small angle x-ray scattering) and determined the biological activity in vitro and in vivo. The structural and functional coherencies in the LNPs were compared in those of lipoplexes, and the effects of selected lipids were highlighted. Such understanding of the molecular basis of delivery complexes will help to identify criteria for the development of improved mRNA delivery vehicles for clinical development.
{"title":"Structure-Function Correlation in Novel Nanomedicines for RNA Delivery","authors":"Sara S. Nogueira, J. Moreno, H. Haas, K. Reuter, Stephanie Erbar, Peter Languth","doi":"10.11159/NDDTE17.118","DOIUrl":"https://doi.org/10.11159/NDDTE17.118","url":null,"abstract":"Extended Abstract Messenger RNA (mRNA)-based nanomedicines constitute a new class of pharmaceutical products, with a variety of potential applications, ranging from tumour immunotherapy to protein substitution. For patient administration, mRNA can be formulated in different types of nanoparticle vehicles, in order to protect the mRNA from degradation and facilitate uptake resulting in expression at the target site. BioNTech has brought the first intravenously injectable mRNA nanoparticle product for cancer immunotherapy into clinical trials, which consist of a lipoplex formulation obtainable from cationic liposomes [1, 2]. Lipid nanoparticles (LNPs) are another type of delivery vehicle and have been successfully used in the past, for example, to deliver siRNA to the liver [3]. Recently, LNPs have been also been used as carriers for mRNA, for induction potent CD8 T cell immune response [4], showing that LNPs can be versatile delivery systems for RNA in diverse therapeutic settings. Typically, LNPs are comprised of an ionizable lipid, one or several helper lipids and a polyethylene glycol (PEG). The ionizable lipid, which is positively charged at low pH and neutral at high pH, is selected to allow high RNA encapsulation and efficacy and to facilitate endosomal escape. The activity of the mRNA LNP formulations strongly depends on the type of ionisable lipid, on the lipid composition, the lipid to RNA ratio, and several other molecular and structural parameters. Furthermore, the activity may vary also for different application routes (e.g., intravenous, intramuscular, subcutaneous), or if therapeutic approaches are intended. So far, there is no clear common understanding on the correlation between the molecular parameters of the LNPs and the biological activity. Therefore, in our study we have systematically studied certain molecular and formulation parameters of mRNA loaded LNPs, in order to correlate them with the biological function. In particular we have thoroughly investigated physicochemical characteristics (internal organization, fluidity, size) and the structure of the LNPs (in particular by small angle x-ray scattering) and determined the biological activity in vitro and in vivo. The structural and functional coherencies in the LNPs were compared in those of lipoplexes, and the effects of selected lipids were highlighted. Such understanding of the molecular basis of delivery complexes will help to identify criteria for the development of improved mRNA delivery vehicles for clinical development.","PeriodicalId":31009,"journal":{"name":"RAN","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81432297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yu. A. Malinovskaya, S. Gelperina, O. Maksimenko, V. Baklaushev
Yulia Malinovskaya, Svetlana Gelperina, Olga Maksimenko, Vladimir Baklaushev R-Pharm Drugs Technology Ltd. Khimki, Moscow Region, 141400, Russia Serbsky State Scientific Center for Social and Forensic Psychiatry Moscow, 117418, Russia j.malinowskaya@gmail.com Extended Abstract Introduction: Our previous results demonstrated a considerable antitumor effect of doxorubicin loaded in PLGA nanoparticles (Dox-PLGA NPs) coated with poloxamer 188 (P188) against the intracranial 101.8 glioblastoma in rats [1,2]. As a high-grade breast cancer is a common cause of brain metastases occurring in at least 10-16% patients [3] and doxorubicin is widely used against breast cancer, the aim of the present study was to evaluate the efficiency of Dox-PLGA NPs against 4T1 metastatic breast cancer in Balb/c mice. Methods: Dox-PLGA NPs were prepared by a double emulsion solvent evaporation technique. Chemotherapy: 4T1 murine breast cancer cells were previously modified by firefly luciferase gene transfection (4Т1-Luc2) and inoculated intracardially (1 10) into the cavity of a left ventricle of female Balb/c mice. On days 7, 10, 13, 16, and 19 after intracardial injection the tumor-bearing animals received i.v. the following formulations in the dose of 2 mg/kg (as doxorubicin): 1) Doxorubicin solution (Dox-sol), 2) Dox-PLGA NPs in PBS (DOX-PLGA), 3) Dox-PLGA NPs coated with 1% poloxamer 188 (Dox-PLGA/P188). For coating the NPs were resuspended in 1% P188 30 min before injection. Animals treated with 1% P188 solution and untreated group were used as controls 1 and 2, respectively. Organ bioluminescence intensity was assessed using an intravital fluorescence imaging system Ivis Spectrum CT on days 14 and 28 after tumor inoculation. Additionally, the presence of metastases in surviving animals was confirmed by MRI on days 21 and 28. Results: The average particle diameter was 120-130 nm, and the drug loading was 84%. The mean survival time of tumour-bearing mice was increased by >40% after treatment with Dox-PLGA NPs, as compared to control (23 days versus 15-16 days, respectively). As shown by intravital fluorescence imaging, the improved survival in the nanoparticle-treated groups also correlated with significantly lower fluorescence intensity of metastases as compared to the group treated with Dox-sol and control groups. The difference between the groups treated with DOX-PLGA and Dox-PLGA/P188 was not significant; however, in the animals treated with P188-coated NPs a somewhat lower bioluminescence of metastases was observed. Importantly, administration of nanoparticulate formulations was associated with a significantly improved tolerance of chemotherapy, as compared to free doxorubicin. Conclusion: Binding of doxorubicin to PLGA nanoparticles considerably enhanced its antitumour efficacy against 4T1 metastatic breast cancer in mice providing more pronounced inhibition of metastatic spread and higher increase of animal life-span, as compared to the free drug. Moreover,
{"title":"Considerable Anti-tumour Effect of Nanoparticle-Bound Doxorubicin against 4T1 Metastatic Breast Cancer in Mice","authors":"Yu. A. Malinovskaya, S. Gelperina, O. Maksimenko, V. Baklaushev","doi":"10.11159/nddte17.108","DOIUrl":"https://doi.org/10.11159/nddte17.108","url":null,"abstract":"Yulia Malinovskaya, Svetlana Gelperina, Olga Maksimenko, Vladimir Baklaushev R-Pharm Drugs Technology Ltd. Khimki, Moscow Region, 141400, Russia Serbsky State Scientific Center for Social and Forensic Psychiatry Moscow, 117418, Russia j.malinowskaya@gmail.com Extended Abstract Introduction: Our previous results demonstrated a considerable antitumor effect of doxorubicin loaded in PLGA nanoparticles (Dox-PLGA NPs) coated with poloxamer 188 (P188) against the intracranial 101.8 glioblastoma in rats [1,2]. As a high-grade breast cancer is a common cause of brain metastases occurring in at least 10-16% patients [3] and doxorubicin is widely used against breast cancer, the aim of the present study was to evaluate the efficiency of Dox-PLGA NPs against 4T1 metastatic breast cancer in Balb/c mice. Methods: Dox-PLGA NPs were prepared by a double emulsion solvent evaporation technique. Chemotherapy: 4T1 murine breast cancer cells were previously modified by firefly luciferase gene transfection (4Т1-Luc2) and inoculated intracardially (1 10) into the cavity of a left ventricle of female Balb/c mice. On days 7, 10, 13, 16, and 19 after intracardial injection the tumor-bearing animals received i.v. the following formulations in the dose of 2 mg/kg (as doxorubicin): 1) Doxorubicin solution (Dox-sol), 2) Dox-PLGA NPs in PBS (DOX-PLGA), 3) Dox-PLGA NPs coated with 1% poloxamer 188 (Dox-PLGA/P188). For coating the NPs were resuspended in 1% P188 30 min before injection. Animals treated with 1% P188 solution and untreated group were used as controls 1 and 2, respectively. Organ bioluminescence intensity was assessed using an intravital fluorescence imaging system Ivis Spectrum CT on days 14 and 28 after tumor inoculation. Additionally, the presence of metastases in surviving animals was confirmed by MRI on days 21 and 28. Results: The average particle diameter was 120-130 nm, and the drug loading was 84%. The mean survival time of tumour-bearing mice was increased by >40% after treatment with Dox-PLGA NPs, as compared to control (23 days versus 15-16 days, respectively). As shown by intravital fluorescence imaging, the improved survival in the nanoparticle-treated groups also correlated with significantly lower fluorescence intensity of metastases as compared to the group treated with Dox-sol and control groups. The difference between the groups treated with DOX-PLGA and Dox-PLGA/P188 was not significant; however, in the animals treated with P188-coated NPs a somewhat lower bioluminescence of metastases was observed. Importantly, administration of nanoparticulate formulations was associated with a significantly improved tolerance of chemotherapy, as compared to free doxorubicin. Conclusion: Binding of doxorubicin to PLGA nanoparticles considerably enhanced its antitumour efficacy against 4T1 metastatic breast cancer in mice providing more pronounced inhibition of metastatic spread and higher increase of animal life-span, as compared to the free drug. Moreover, ","PeriodicalId":31009,"journal":{"name":"RAN","volume":"7 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82298703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Extended Abstract Alzheimer's disease is one of the most prevalent neurodegenerative diseases in the world. The neuropathological hallmark of Alzheimer's disease is extracellular deposit of amyloid-β (Aβ) in the brain. Microglial cells are able to remove of Aβ aggregates by receptor-dependent endocytosis [1,3]. Nanotechnology is one of the fastest developing science discipline and nanoparticles (NPs), due to their strong absorption properties are widely used in industry, and also in medical diagnosis and treatment. It was documented that NPs can prevent the formation of Aß-aggregates whereby reducing their neurotoxicity and likely can impact on the Aß-uptake by microglia [2,4-7]. It is supposed that NPs can increase number of emerging phagocytosis bubbles and the Aβ uptake due to the co-transport phenomenon, or in contrary reduce the number of lipid rafts available and therefore inhibit of Aβ transport by some kind of competition. Moreover, by activating different paths to cell signaling, NPs can probably change the expression of the amyloid β-receptors on microglia cell membranes. The goal of our study was to verify whether silver nanoparticles (AgNPs, 20 nm, BSA coated) can change the ability of microglial scavenger receptor 1 (Scara1) for the Aß (1-42) uptake and influence gene or protein expression of these receptors in mouse BV-2 cells. The results from flow cytometry indicate that both Aβ and AgNPs are taken up by microglial cells using the same receptor: AgNPs (50 μg/ml) can decrease the uptake of Aβ by about 80% compared to the control group and Scara1 inhibitor (poliinosinic acid) diminish both AgNPs and Aß peptide uptake. Real-time PCR analysis showed that AgNPs did not change the Scara1 gene expression. The Western blotting (measuring the whole receptor content) revealed a slight decrease in the protein receptor level after treatment of cells with AgNPs (50 μg/ml). On the other hand, the content of the receptor on the cell surface, measured cytometrically, was greatly diminished in the presence of AgNPs. In summary, AgNPs clearly blocked the receptor and so they may play rather disadvantageous role in Aβ removal. Results from the Project “The influence of nanoparticles on beta-amyloid removal by microglia cells”. From National Science Centre, Project duration: 09. 2014-09.2017 Project ID:UMO-2013/11/N/NZ7/00415.
{"title":"The Effect of Silver Nanoparticles on the Scavenger Receptor-Scara1 on Microglia","authors":"Sikorska Katarzyna, Grądzka Iwona, Wasyk Iwona","doi":"10.11159/icnb17.115","DOIUrl":"https://doi.org/10.11159/icnb17.115","url":null,"abstract":"Extended Abstract Alzheimer's disease is one of the most prevalent neurodegenerative diseases in the world. The neuropathological hallmark of Alzheimer's disease is extracellular deposit of amyloid-β (Aβ) in the brain. Microglial cells are able to remove of Aβ aggregates by receptor-dependent endocytosis [1,3]. Nanotechnology is one of the fastest developing science discipline and nanoparticles (NPs), due to their strong absorption properties are widely used in industry, and also in medical diagnosis and treatment. It was documented that NPs can prevent the formation of Aß-aggregates whereby reducing their neurotoxicity and likely can impact on the Aß-uptake by microglia [2,4-7]. It is supposed that NPs can increase number of emerging phagocytosis bubbles and the Aβ uptake due to the co-transport phenomenon, or in contrary reduce the number of lipid rafts available and therefore inhibit of Aβ transport by some kind of competition. Moreover, by activating different paths to cell signaling, NPs can probably change the expression of the amyloid β-receptors on microglia cell membranes. The goal of our study was to verify whether silver nanoparticles (AgNPs, 20 nm, BSA coated) can change the ability of microglial scavenger receptor 1 (Scara1) for the Aß (1-42) uptake and influence gene or protein expression of these receptors in mouse BV-2 cells. The results from flow cytometry indicate that both Aβ and AgNPs are taken up by microglial cells using the same receptor: AgNPs (50 μg/ml) can decrease the uptake of Aβ by about 80% compared to the control group and Scara1 inhibitor (poliinosinic acid) diminish both AgNPs and Aß peptide uptake. Real-time PCR analysis showed that AgNPs did not change the Scara1 gene expression. The Western blotting (measuring the whole receptor content) revealed a slight decrease in the protein receptor level after treatment of cells with AgNPs (50 μg/ml). On the other hand, the content of the receptor on the cell surface, measured cytometrically, was greatly diminished in the presence of AgNPs. In summary, AgNPs clearly blocked the receptor and so they may play rather disadvantageous role in Aβ removal. Results from the Project “The influence of nanoparticles on beta-amyloid removal by microglia cells”. From National Science Centre, Project duration: 09. 2014-09.2017 Project ID:UMO-2013/11/N/NZ7/00415.","PeriodicalId":31009,"journal":{"name":"RAN","volume":"44 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86781084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Extended Abstract In tissue engineering, natural/synthetic polymer based fibrous composite scaffolds obtained via electrospinning method were shown to support the cell adhesion and tissue regeneration. However, electrospinning of natural polymers requires the use of toxic solvents that are negatively affecting the cell proliferation and biocompatibility of the produced scaffolds in addition to the usage of acidic solvents which will result in massive biodegradation inside the body[1] .Here, a method was proposed that is higher safety for the patient and even for the experimentalists who are using harmful and highly volatile solvents. Two types of polymers were used in the synthesis of the scaffolds by mimicking the key features of the tissue extracellular matrix which contains gelatin and coaxially organized nanofibers. Coaxial electrospinning technique was used to obtain core(PVA)-shell (gelatin) nanofibers. While material in the shell provides recognition sites for the tissue cells, core material provides mechanical endurance. Different from conventional methods, proposed work aims to lower the steps of application of the scaffold to the harmed tissue by using only deionized water as solvent. Instead of dissolving PVA and gelatin in toxic and acidic solvents, they were dissolved in the deionized water above the gelation temperature. Later, coaxial electrospinning generated increased cell spread and mechanical stiffness. The samples were characterized by scanning and transmission electron microscopy. Based on the experimental results it is concluded that electrospun fibers obtained from the 8% concentrated gelatin solution had a beaded structure, whereas the coaxially fabricated PVA and gelatin from the same concentration solutions did not show any beaded morphology. Also core-shell fibers have diameters down to 180 nm. This result showed that PVA aids to the uniform gelatin fiber formation which, may give higher mechanical stability. The electron microscopy analysis leading to these results has received support by the Nanotechnology Research and Application Center at Sabanci University.
{"title":"Green Manufacturing of Core-Shell Polyvinyl Alcohol-Gelatin Electrospun Nanofiber Scaffolds","authors":"Mustafa Şengör, M. A. Gulgun, S. Altıntaş","doi":"10.11159/icnb17.106","DOIUrl":"https://doi.org/10.11159/icnb17.106","url":null,"abstract":"Extended Abstract In tissue engineering, natural/synthetic polymer based fibrous composite scaffolds obtained via electrospinning method were shown to support the cell adhesion and tissue regeneration. However, electrospinning of natural polymers requires the use of toxic solvents that are negatively affecting the cell proliferation and biocompatibility of the produced scaffolds in addition to the usage of acidic solvents which will result in massive biodegradation inside the body[1] .Here, a method was proposed that is higher safety for the patient and even for the experimentalists who are using harmful and highly volatile solvents. Two types of polymers were used in the synthesis of the scaffolds by mimicking the key features of the tissue extracellular matrix which contains gelatin and coaxially organized nanofibers. Coaxial electrospinning technique was used to obtain core(PVA)-shell (gelatin) nanofibers. While material in the shell provides recognition sites for the tissue cells, core material provides mechanical endurance. Different from conventional methods, proposed work aims to lower the steps of application of the scaffold to the harmed tissue by using only deionized water as solvent. Instead of dissolving PVA and gelatin in toxic and acidic solvents, they were dissolved in the deionized water above the gelation temperature. Later, coaxial electrospinning generated increased cell spread and mechanical stiffness. The samples were characterized by scanning and transmission electron microscopy. Based on the experimental results it is concluded that electrospun fibers obtained from the 8% concentrated gelatin solution had a beaded structure, whereas the coaxially fabricated PVA and gelatin from the same concentration solutions did not show any beaded morphology. Also core-shell fibers have diameters down to 180 nm. This result showed that PVA aids to the uniform gelatin fiber formation which, may give higher mechanical stability. The electron microscopy analysis leading to these results has received support by the Nanotechnology Research and Application Center at Sabanci University.","PeriodicalId":31009,"journal":{"name":"RAN","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76977563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Ficai, M. Sonmez, Roxana Doina Trusc, B. Vasile, Denisa Fica, E. Andronescu
Anton Ficai, Maria Sonmez, Roxana Doina Trusca, Bogdan Stefan Vasile, Denisa Ficai, Ecaterina Andronescu Department of Science and Engineering of Oxide Materials and Nanomaterials, Faculty of Applied Chemistry and Materials Science, University Politehnica of Bucharest 1-7 Gh. Polizu St., 011061-Bucharest, Romania anton.ficai@upb.ro; ficaimaria@yahoo.com National Research & Development Institute for Textiles and Leather–division: Leather and Footwear Research Institute, Bucharest, Romania
Anton Ficai, Maria Sonmez, Roxana Doina Trusca, Bogdan Stefan Vasile, Denisa Ficai, Ecaterina Andronescu，布加勒斯特理工大学应用化学与材料科学学院氧化材料与纳米材料科学与工程系波利祖街，011061-布加勒斯特，罗马尼亚anton.ficai@upb.ro;ficaimaria@yahoo.com国家纺织和皮革研究与发展研究所:皮革和鞋类研究所，布加勒斯特，罗马尼亚
{"title":"Design of TiOxNy for Developing Layered Stent Technology","authors":"A. Ficai, M. Sonmez, Roxana Doina Trusc, B. Vasile, Denisa Fica, E. Andronescu","doi":"10.11159/icnnfc17.137","DOIUrl":"https://doi.org/10.11159/icnnfc17.137","url":null,"abstract":"Anton Ficai, Maria Sonmez, Roxana Doina Trusca, Bogdan Stefan Vasile, Denisa Ficai, Ecaterina Andronescu Department of Science and Engineering of Oxide Materials and Nanomaterials, Faculty of Applied Chemistry and Materials Science, University Politehnica of Bucharest 1-7 Gh. Polizu St., 011061-Bucharest, Romania anton.ficai@upb.ro; ficaimaria@yahoo.com National Research & Development Institute for Textiles and Leather–division: Leather and Footwear Research Institute, Bucharest, Romania","PeriodicalId":31009,"journal":{"name":"RAN","volume":"59 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73240694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
S. Mazzucchelli, Marta Truff, M. Bellini, M. Rizzuto, D. Prosperi, F. Corsi
Serena Mazzucchelli, Marta Truffi, Michela Bellini, Maria A. Rizzuto, Davide Prosperi, Fabio Corsi Department of Biomedical and Clinical Sciences, University of Milan Via G. B. Grassi 74, 20157 Milan, Italy serena.mazzucchelli@gmail.com; marta.truffi@unimi.it Surgery Department, Breast Unit, ICS Maugeri S. p. A. SB Pavia, Italy fabio.corsi@unimi.it Department of Biotechnology and Biosciences, University of MilanBicocca Piazza della Scienza 2, 20126 Milan, Italy michi.bellini@gmail.com; m.rizzuto3@campus.unimib.it; davide.prosperi@unimib.it
Serena Mazzucchelli, Marta Truffi, Michela Bellini, Maria A. Rizzuto, Davide Prosperi, Fabio Corsi米兰大学生物医学与临床科学系Via g.b. Grassi 74, 20157意大利米兰serena.mazzucchelli@gmail.com;marta.truffi@unimi.it意大利帕维亚ICS Maugeri s.p . A. SB乳房外科fabio.corsi@unimi.it米兰比可卡大学生物技术与生物科学系，20126意大利米兰michi.bellini@gmail.com;m.rizzuto3@campus.unimib.it;davide.prosperi@unimib.it
{"title":"Metronomic Nanocaged Doxorubicin Prevents Chemoresistance and Cardiotoxicity in Breast Cancer","authors":"S. Mazzucchelli, Marta Truff, M. Bellini, M. Rizzuto, D. Prosperi, F. Corsi","doi":"10.11159/NDDTE17.123","DOIUrl":"https://doi.org/10.11159/NDDTE17.123","url":null,"abstract":"Serena Mazzucchelli, Marta Truffi, Michela Bellini, Maria A. Rizzuto, Davide Prosperi, Fabio Corsi Department of Biomedical and Clinical Sciences, University of Milan Via G. B. Grassi 74, 20157 Milan, Italy serena.mazzucchelli@gmail.com; marta.truffi@unimi.it Surgery Department, Breast Unit, ICS Maugeri S. p. A. SB Pavia, Italy fabio.corsi@unimi.it Department of Biotechnology and Biosciences, University of MilanBicocca Piazza della Scienza 2, 20126 Milan, Italy michi.bellini@gmail.com; m.rizzuto3@campus.unimib.it; davide.prosperi@unimib.it","PeriodicalId":31009,"journal":{"name":"RAN","volume":"10 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81167813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Tatar, T. Nagy-Simon, A. Jurj, I. Berindan‐Neagoe, C. Tomuleasa, D. Cialla‐May, S. Aștilean, S. Boca
{"title":"Anti-CD19 Gold Nanostars as New Therapeutic Vectors for the Treatment of Acute Lymphoblastic Leukemia","authors":"A. Tatar, T. Nagy-Simon, A. Jurj, I. Berindan‐Neagoe, C. Tomuleasa, D. Cialla‐May, S. Aștilean, S. Boca","doi":"10.11159/nddte17.116","DOIUrl":"https://doi.org/10.11159/nddte17.116","url":null,"abstract":"","PeriodicalId":31009,"journal":{"name":"RAN","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89880392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：